Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients: A proof-of-concept study.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
revised:
06
03
2024
received:
22
01
2024
accepted:
11
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
2
4
2024
Statut:
aheadofprint
Résumé
Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients. Data showed decreased glycolytic activity in red blood cells of 2/3 of patients with lower-risk MDS. These results highlight a potential effect of the PK activator in this setting.
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agios Pharmaceuticals
ID : Provided AG946 and reagents.
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Balaian E, Wobus M, Bornhäuser M, Chavakis T, Sockel K. Myelodysplastic syndromes and metabolism. Int J Mol Sci. 2021;22(20):11250.
Tani K, Fujii H, Takahashi K, et al. Erythrocyte enzyme activities in myelodysplastic syndromes: elevated pyruvate kinase activity. Am J Hematol. 1989;30(2):97‐103.
Lintula R. Red cell enzymes in myelodysplastic syndromes: a review. Scand J Haematol Suppl. 1986;45:56‐59.
Rab M, Van Dijk MJ, Bos J, et al. Pharmacodynamic effects of AG‐946, a highly potent next‐ generation activator of pyruvate kinase, in ex vivo treatment of red blood cells from sickle cell disease patients. Blood. 2021;138(suppl 1):2029‐2031.
A Study of AG‐946 in Participants With Anemia Due to Lower‐Risk Myelodysplastic Syndromes (LR‐MDS). NCT05490446. Last accessed on 8 August 2023.
D'Alessandro A, Anastasiadi AT, Tzounakas VL, et al. Red blood cell metabolism in vivo and in vitro. Metabolites. 2023;13(7):793.